Supporting Information

Dual Enzyme-like Co-$FeSe_2$ Nanoflowers with GSH Degradation Capability for NIR II-Enhanced Catalytic Tumor Therapy

Jingge Zhang,[a] *Enna Ha,*[a] *Danyang Li,*[a] *Shuqing He,*[a] *Luyang Wang*[b] *and Junqing Hu**[a,c]

[a] College of Health Science and Environmental Engineering, Shenzhen Technology University, Shenzhen, Guangdong 518118, PR China

[b] College of New Materials and New Energies, Shenzhen Technology University, Shenzhen, Guangdong 518118, PR China

[c] Shenzhen Bay Laboratory, Shenzhen, Guangdong 518055, China

*Corresponding author e-mail: haenna@sztu.edu.cn; hujunqing@sztu.edu.cn



Fig. S1. SEM images of different synthetic condition: (a) V_{OM}: V_{DDT} =1:2; (b) V_{OM}: V_{DDT} =1:1; (c) V_{OM}: V_{DDT} =2:1.

Table S1 EDS result of Co-$FeSe_2$

Sample	Mass ratio (%)	Atomic ratio (%)
Co	1.72	2.08
Fe	25.49	32.42
Se	72.79	65.50



Fig. S2. EDS spectrum of Co-$FeSe_2$ nanozymes.



Fig. S3. (a) TEM of modified Co-$FeSe_2$ and (b) FT-IR spectra of DSPE-PEG, Co-$FeSe_2$, DSPE-PEG modified Co-$FeSe_2$.



Fig. S4. DLS of modified Co-$FeSe_2$ dispersed in (a) PBS and (b) complete medium within 7 days.



Fig. S5. Fitting plots of time versus −lnθ during the cooling period.



Fig. S6. (a) UV-Vis of modified Co-$FeSe_2$. (b) Temperature change profile of modified Co-$FeSe_2$ (1064 nm, 0.8 W/cm^2).



Fig. S7. Raw data of western blot experiment. Group i) Control, ii) NIR, 1064 nm, 0.8 W/cm^2, 10 min, iii) Co-$FeSe_2$, 200 μg/mL, iv) Co-$FeSe_2$-NIR.



Fig. S8. CLSM imaging of mitochondrial morphology in 4T1 cells after different treatments, scale bar: 50 μm. Group i) Control, ii) NIR, 1064 nm, 0.8 W/cm^2, 10 min, iii) Co-$FeSe_2$, 200 μg/mL, iv) Co-$FeSe_2$-NIR



Fig. S9. HE staining images of the excised organs (heart, liver, spleen, lung, kidney) of BALB/c tumor-bearing mice at 14th day after treatment.